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often respond poorly to treatment and require prolonged rehabilitation. Therapeutic options used to repair
ruptured tendons have consisted of suture, autografts, allografts, and synthetic prostheses. To date, none of
these alternatives has provided a successful long-term solution, and often the restored tendons do not recover
their complete strength and functionality. Unfortunately, our understanding of tendon biology lags far behind
that of other musculoskeletal tissues, thus impeding the development of new treatment options for tendon con-
ditions. Hence, in this review, after introducing the clinical signiﬁcance of tendon diseases and the present under-
standing of tendon biology,we describe and critically assess the current strategies for enhancing tendon repair by
biological means. These consist mainly of applying growth factors, stem cells, natural biomaterials and genes,
alone or in combination, to the site of tendon damage. A deeper understanding of how tendon tissue and cells
operate, combined with practical applications of modern molecular and cellular tools could provide the long
awaited breakthrough in designing effective tendon-speciﬁc therapeutics and overall improvement of tendon
disease management.
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Tendons are unique forms of connective tissue that connect and
transmit forces from muscle to bone [1]. They are able to store elastic
energy and withstand the high tensile forces upon which locomotion
is entirely dependent [2]. This review article is designed:
(1) to provide background information on the clinical relevance of
tendons and to remind the reader of the lengthy and incomplete
nature of the native tendon repair process. This motivates the
urgent need for improving the outcome of tendon repair; bio-
logics offer attractive possibilities in this regard;
(2) to introduce the basic tissue and cellular organization of tendon
and its major tendon-speciﬁc molecules (Sections 1.1–1.3);
(3) to summarize the results of studies based on the four main ap-
proaches - growth factors (Section 2.1), stem cells (2.2), natural
biomaterials (2.3) and gene therapy (2.4);
(4) to discuss critically unresolved issues.
We have focused on in vivo studies of the repair of tendon injury,
and only in some cases included in vitro examples to strengthen certain
points.
1.1. Tendon clinical relevance
Primary disorders of tendons (tendinopathies), due to overuse or
age-related degeneration, are widely distributed clinical problems in
society, possibly resulting in acute or chronic tendon injuries. Hospital
evidence and statistical data suggest that certain tendons are more
prone to pathology than others; these are the rotator cuff, Achilles,
tibialis posterior and patellar tendons, whose pathologies are often
based on a degenerative process. In addition, the extensor and ﬂexor
tendons of the hand and ﬁngers are frequently subjected to direct lacer-
ations at all ages. Although there are no accurate ﬁgures speciﬁcally re-
lating to tendon disorders, studies from primary care show that 16% of
the general population suffer from rotator cuff-related shoulder pain
[3] and this rises to 21% when the statistics shift to elderly hospital
and community populations [3,4]. These numbers further increase in
the sports community; for example, Kannus reported that 30 to 50% of
all sporting injuries involve tendons [5].
Although there are a number of studies discussing this issue, there is
still a need to clarify the classiﬁcation and terminology of the different
tendon pathologies. This situation is mainly due to the clinical problem
that tendon biopsies are generally difﬁcult to obtain and that this mate-
rial is usually collected at the end-stage of the condition or after tendon
rupture. In general, themajor conditions affecting tendons are tendinitis
and tendinosis; the ﬁrst assumed to be accompanied by inﬂammationand pain, whereas the second can be caused by tendinous degeneration
[6]. It is believed that these conditions are rarely spontaneous [7] and
are not caused by single factors. Rather, they are the end result of a
variety of pathological processes [8,9] which can ultimately lead to the
main clinical problem: loss of tissue integrity with full or partial rupture
of the tendon.
Many factors are likely to be involved in the onset and progression of
tendinopathies. Intrinsic factors include age, gender, anatomical variants,
body weight, and systemic disease. Extrinsic factors include sporting
activities, physical loading, occupation, and environmental conditions
such as walking surfaces or footwear [8,9]. In addition, it has been re-
ported that genetic polymorphisms affecting collagen ﬁber formation
[10] or even blood group [11] are associated with tendon injuries and
tendinopathy.
Hence, tendinopathies representmajormedical problems associated
with physical activity and age-related degeneration. Unfortunately, due
to hypocellularity and hypovascularity, the natural healing ability of
tendons is extremely low and inefﬁcient [12]. Nevertheless, healthy
tendon tissue has the potential to heal by itself as long as the ruptured
parts have contact and the well vascularized peritendinous tissue, the
so-called paratenon, is intact [13]. There is continuing debate on whether
to treat acute Achilles tendon ruptures operatively or conservatively [14].
Both options have their advantages. In the case of rotator cuff pathologies,
the choice of therapy very much depends on the patient's age, degree of
tendon degeneration and extent of laceration [15]. A ruptured patellar
tendon needs to be treated operatively to restore the extensor apparatus
of the knee [16]. The treatment of tibial tendon insufﬁciencies is stage-
dependent [17].
The main surgical repair techniques aim to re-establish tendon
alignment by suturing the ruptured ends together, which requires a
non-degenerate tendon with healing potential. The reconstructions
are limited by the tendon's biology. Sometimes an autograft is used to
bridge certain defects, while use of allografts has increased in recent
years [18,19]. When autografts are used, a certain donor side morbidity
must not be neglected. And in both cases, ingrowth of the bridging graft
is necessary, requiring good tissue conditionswithout degeneration. It is
estimated that $30 billion are spent on musculoskeletal injuries in the
United States each year and tendon/ligament injuries represent approx-
imately 45% of these cases [20]. In addition, surgical repairs are often
unsuccessful inwhich case themajority of these injuries become essen-
tially chronic conditions that are prone to recur [21].
In summary, tendon disorders are common, debilitating conditions
affecting both the working population and recreational athletes. Their
etiology remains controversial, particularly in understanding which
factors are primary and which are secondary to the disorder. Moreover,
these conditions not only have an impact on peoples' quality of life, but
also represent an enormous economic burden on the worldwide
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key molecular and cellular processes involved in the progression of
tendinopathies and subsequent ruptures in order to develop effective
therapeutic strategies for treating them.
1.2. Tendon molecular composition and cell niche
The extracellular matrix (ECM) of tendons is composed of collagen
and a smaller fraction of elastin embedded in a hydrated proteoglycan
matrix. The principal role of the collagen ﬁbers is to resist to tension,
whereas proteoglycans are primarily responsible for the viscoelastic
properties of the tendon. The smallest structural unit is the collagen
ﬁbril. Each ﬁbril is built from soluble tropocollagen molecules forming
cross-links to create insoluble collagenmolecules which then aggregate
progressively into microﬁbrils, ﬁbrils and ﬁnally into ﬁbers. Bundles of
ﬁbers are bound together by thin layers of loose connective tissues
known as the epi- and endotenon, which allow the ﬁber groups to
glide on each other in an almost frictionless manner; they also carry
blood vessels, nerves and lymphatics to the deeper portion of the
tendon [2]. The smooth gliding of tendons as they move is aided by
the lubricating molecule, lubricin [22]. Altogether this complex, three-
dimensional, internal ultrastructure endows the tendon with high
tensile force and resilience, while preventing damage and separation
of the ﬁbers under mechanical stress [8] (Fig. 1).
Collagen type I is themost abundantmolecule in the ECM, accounting
for almost 60% of the drymass of the tissue and approximately 95% of the
total collagen [8]. Type III is the next most abundant collagen [23].
Normally, collagen type III is restricted to the tendon sheets; however, it
is found abundantly in pathological tendons and it is also theﬁrst collagen
to be produced in high quantity during tendon healing [8]. Other colla-
gens in tendon include types V, VI, XII, XIV and XV.
Besides collagen ﬁbers, the tendon ECM is composed of many other
components including elastic ﬁbers, the ground substance and inorganic
components. In general, elastic ﬁbers ensure tissueﬂexibility and extensi-
bility, permitting long-range deformability and passive recoil without
energy input [24]. Furthermore, they are thought to be involved in theFig. 1. A schematic drawing of basic tendon structure. The collagen molecules are orga-
nized hierarchically in ﬁbrils, ﬁbers and fascicles. The cellular content is dominated by
the tenocytes, which are terminally differentiated cells. Tendons contain stem and pro-
genitor cell populations, whose exact location is still debated (therefore indicated with
a?). Different sheets, endotenon and epitenon (loose connective tissues), and paratenon
(fatty areolar tissue) are shown as well as blood vessels and nerves.
Based on [227].recovery of the crimppattern of the collagenﬁbers after tendon stretching
[25]. The ground substance comprises hyaluronan, proteoglycans
(decorin, biglycan, ﬁbromodulin, lumican), structural glycoproteins and
a wide variety of other molecules. The highly viscous and hydrophilic
nature of the ground substance provides spacing and further support of
the collagen ﬁbers. Water makes up 60 to 80% of the total weight of the
ground substance, whereas proteoglycans account only for 1–2% [23].
Mature tendons are normally characterized by low cellular density
(Fig. 1). Approximately 90–95% of the cellular content of tendon com-
prises tendon-speciﬁc cell types described in the literature as tenoblasts
and tenocytes, the latter being terminally differentiated [26]. Other cell
types include the synovial cells of the tendon sheaths, chondrocytes at
the pressure and insertion sites, and vascular cells. Tendon cells are
able to synthesize all components of the tendon ECMwith a peak activity
during growth and a gradual decrease during aging [26]. It is thought that
the lowmetabolic rates with anaerobic energy production typical of ma-
ture tendon cells can reduce the risk of ischemia and necrosis, especially
during the extended periods of tensional stresses to which tendons are
usually subjected. On the other hand, this feature is a disadvantage for ten-
don recovery and healing. Conversion of tenoblasts to tenocytes might
occur in response to various stimuli such as exercise and trauma in which
higher rates of proliferation and matrix remodeling are needed [26].
In 2007, Bi et al., identiﬁedwithin human hamstring tendons a novel
cell population of resident tendon stem/progenitor cells (TSPC) [27]. It
was shown that the TSPC exhibit classical adult mesenchymal stem
cell (MSC) criteria such as presence of speciﬁc surface antigens, self-
renewal, clonogenicity and three-lineage differentiation (adipogenic,
osteogenic and chondrogenic), but also that they express tendon-
related genes such as scleraxis and tenomodulin, and are able to form
tendon and enthesis-like tissues when implanted in vivo. The existence
of TSPC was further conﬁrmed in subsequent studies with human,
equine, rabbit, rat and mouse tendons [28–35]. Whether adult TSPCs
represent a residual population of the embryonal tendon progenitors re-
mains still unclear. Furthermore, there is a need for studies demonstrating
the exact roles and location of TSPC during tendon maintenance and
healing as well as their exact relationship to tenoblasts and tenocytes. At
present, the direct comparison of TSPCs to tenoblasts and tenocytes is im-
pededby the lackofmolecularmarkers allowing their precise identiﬁcation
andhence the isolation of pure subsets of cell populations along the tendon
differentiation cascade. Despite the incomplete understanding of TSPC na-
ture and function, they represent a potential cell source for treating injured
tendons. How the tendon research ﬁeld foresees using TSPC in tendon re-
pair will be discussed later in the review.
1.3. Tendon healing
The lack of detailed molecular and histopathological studies on ten-
dons has hampered our understanding of the mechanisms underlying
tendon healing. Some evidence has been obtained from animal models
of experimentally induced tendon damage [36,37]. In general, the
healing process of an injured or compromised tendon passes through-
out three main phases containing distinctive cellular and molecular
cascades (Figs. 2 and 3). These phases can overlap and their duration
is dependent on the location and severity of the disease [38–40]. The ini-
tial inﬂammatory stage beginswith the formation of a hematoma shortly
after injury. Inﬂammatory cells such as neutrophils,monocytes andmac-
rophages are attracted to the injury site by pro-inﬂammatory cytokines
[38]. Secreted angiogenic factors initiate the formation of a vascular net-
work, which is responsible for the survival of the newly forming ﬁbrous
tissue at the injury site. Despite being profuse and haphazard, the initial
vascular response is essential, since it has been shown that dimunition of
blood supply impairs healing [41]. Next, components of the ECM, pre-
dominantly collagen type III, are synthesized by recruited ﬁbroblasts.
After a few days, the proliferation stage takes place accompanied by
the synthesis of abundant ECM components, including proteoglycans
and collagens (mostly collagen type III), which are arranged in a random
Fig. 2. The tendon repair process in humans. The healing of ruptured tendons passes through three main phases containing distinctive cell and molecular cascades. These phases overlap
and their duration depends upon the location and severity of the tendon injury. Currently, the tendon research ﬁeld is actively exploring the use of growth factors, genes, stem cells and
biomaterials, alone or in various combinations, for enhancing tendon healing. Mostly, the appropriate times of application are in the ﬁrst two stages (indicated by white arrows), and
depend on the type of growth factors, genes, stem cells or biomaterials implemented. Based on [47].
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absorption of large amounts of water. The remodeling stage includes
two sub-stages; it begins 6–8 weeks after injury and takes around
1–2 years depending on the age and condition of the patient. The
ﬁrst sub-stage, consolidation, is characterized by a decrease in cellularity
and matrix production, as the tissue becomes more ﬁbrous through the
replacement of collagen type III by collagen type I. Collagen ﬁbers then
start to organize along the longitudinal axis of the tendon, thereby
restoring tendon stiffness and tensile strength. After approximately
10 weeks, the maturation stage starts, which includes an increase in col-
lagen ﬁbril crosslinking and the formation of more mature tendonous
tissue.
The tendon healing process is complexly orchestrated by a variety of
secretedmolecules [42]. Initially, certain inﬂammatory cytokines, such as
interleukin (IL)-6 and IL-1β, are produced by the invading inﬂammatory
cells. Later, tissue repair is facilitated by a number of growth factors,
which are released by cells located at the injury site. bFGF (basic ﬁbroblast
growth factor), BMPs (bone morphogenetic proteins)-12, -13, and -14
also known as GDFs (growth and differentiation factors) -5, -6 and -7 re-
spectively, TGFβ (transforming growth factor beta), IGF-1 (insulin-like
growth factor-1), PDGF (platelet-derived growth factor) and VEGF
(vascular endothelial growth factor) are involved in different phases
of the healing process with diverse molecular effects (Fig. 3). During the
repair process, tendon cells are activated andboth synthesize anddegradeFig. 3. Keymolecular, cellular andmatrix changes occurring during the threemain phases of ten
activation of certain cell types and production of essential matrix proteins, which collectively co
Based on [45,46].ECM components, thereby participating in the slow, continuous process
of tendon remodeling [39,43,44].
Two cellular mechanisms of tendon healing, known as extrinsic and
intrinsic healing, have been suggested [41,45]. It is now believed that
these two mechanisms normally act cooperatively. The hypothesis is
that ﬁrst ﬁbroblasts and inﬂammatory cells from the tendon periphery,
blood vessels and circulation are attracted to the injured site contributing
to cell inﬁltration and the formation of adhesions. Thereafter, intrinsic
cells from the endotenon are activated as they migrate and proliferate
at the injury site, reorganizing the ECM and giving support to the internal
vascular networking [38,46]. The origin of the reparative cells remains in
debate. In 2007, an enlightening study from Kajikawa et al., used amodel
of tendon injury applied to two different chimeric rats, one expressing
green ﬂuorescent protein (GFP) in circulating mesenchymal cells, and
the other in the patellar tendon. The data were consistent with the
biphasic pattern of tendon healing. This comprises an initial invasion of
circulating MSCs followed by the activation of local cells, which partici-
pate in the proliferative phase and carry out the long remodeling phase
[45].
In most patients, especially aged individuals, the healed tendon usu-
ally does not regain the mechanical properties of the uninjured tissue.
The reduced strength of the repaired tissue compared to the native ten-
don results from reduced integration of collagen ﬁbers with a higher
ratio of collagen type III to collagen type I. As a consequence, the tendondon repair. Each healing stage is characterized by involvement of different growth factors,
ntribute to the replacement of the initial ﬁbrous tissue withmore a tendonous regenerate.
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thus the tendon quality and its functional activity are inferior to that
of healthy tendon.
2. Current biological strategies to augment tendon repair
Experimental approaches for enhancing tendon repair consist mainly
of applying growth factors, singly or in combination, stem cells in native
or genetically modiﬁed form, and biomaterials, alone or cell-loaded, at
the site of tendondamage. In the last decade, the number of studies inves-
tigating the functionality of the above strategies has progressively
increased (Fig. 4). This section of the review will focus primarily on
in vivo studies. It will critically discuss progress and the remaining open
questions for future research to address in order to improve the therapy
of damaged tendons. Two of the most difﬁcult tasks that researchers are
facing during regeneration of tendinous tissues are: ﬁrst, to achieve the
regeneration of a highly specialized and three-dimensional organized
matrix, whose formation implies not only biological but also mechanical
constraints; and second, when using stem or progenitor cells, to prevent
inappropriate plasticity of the exogenous cells, or the transdifferentiation
of the local tenocytes into undesirable lineages leading to, for example, in
situ adipose, cartilaginous or bone tissue formation.
2.1. Growth factors
Tendon injury stimulates the production of a variety of growth
factors at multiple stages in the healing process [40,42] leading to in-
creased cellularity and tissue volume [47]. Increased expression of
growth factors is particularly prominent in the early phases of healing
[48,49]. The following growth factors are important in tendon healing:
bFGF, BMP-12, -13, -14, CTGF (connective tissue growth factor), IGF-1,
PDGF, TGFβ, and VEGF [49–52]. In the following section these factors
are brieﬂy introduced before describing in vitro and in vivo experiments
investigating the role of the factors in tendon healing (Table 1). No
human study investigating recombinant growth factors in tendon
healing has been published in the literature.
2.1.1. bFGF
Chang et al., found upregulated bFGFmRNA inmature tenocytes and
in ﬁbroblasts and inﬂammatory cells surrounding the healing site in the
tendon sheath [53]. Being elevated early in the healing process [48,49],Fig. 4. Studies on the use of biologics for tendon repair. Article countswere carried out after searc
growth factors, stem cells, biomaterials and gene therapy. The articles include in vivo and in vit
strate that in the last decade the tendon research ﬁeld has progressively expanded as represent
enhancing tendon tissue healing. Such cumulative efforts may lead to the development of efﬁcbFGF is well positioned to promote the early events in tendon healing
[54].
2.1.2. BMP
BMP-12, -13, and -14, also known as GDF-7, -6, and -5 respectively,
stimulate mitogenesis, and are established tenogenic factors with the
potential of driving differentiation of MSC in vitro [55] and in vivo [56].
BMPs are elevated early in the tendon healing process, gradually
decreasing thereafter [48,49]. BMP-2 plays a role at the enthesis, the ana-
tomical junction of tendon and ligament to bone. New bone formation
can be induced by BMP-2 within a tendon with comparable characteris-
tics to the enthesis. However, in intratendinous healing this bone forma-
tion is clearly undesirable [57–59].
2.1.3. CTGF
In contrast to the previously described factors, CTGF exhibits a
sustained increase in gene expression persisting over 21 days during
healing of chicken ﬂexor tendons [50]. In the rat supraspinatus injury
model of Würgler-Hauri et al., CTGF was moderately expressed in
both the insertion and midsubstance area throughout all time points
[49].
2.1.4. IGF-I
IGF-1 induces tenocyte migration and increases synthesis of the
ECM, including collagen [60]. Elevated IGF-1 mRNA and protein expres-
sion levels were found in healing rabbit ligaments 3 weeks after injury
and in healing equine tendons after 4 to 8 weeks [61,62]. IGF-1 seems
to be particularly important during the formation and remodeling
stages of healing.
2.1.5. PDGF
Increased PDGF-levels have been found in healing tendons [63].
Elevated expression of the PDGF receptor β was found by Chan et al.,
to persist for over 6 months after tendon injury, potentially indicating
the important role of PDGF during the entire tendon repair period [64].
2.1.6. TGFβ
Besides tendon cell migration and mitogenesis, TGFβ especially
stimulates production of the ECM, including increases in the production
of collagen types I and III by all the 3 isoforms TGFβ1, TGFβ2, and
TGFβ3 [65]. High levels of expression and activity of TGFβ are found
throughout the course of tendon-healing [66,67]. Resident tenocyteshing in PubMedusing the following keywords: tendon repair/healing in combinationwith
ro studies, and some articles scored inmore then one category. The search results demon-
ed by the continuous increase in the number of articles focusing on different strategies for
ient biologics for tendon repair.
Table 1
Summary of in vitro and in vivo studies on growth factors.
Growth
factor
Tendon Type of study Model Reference
bFGF Flexor tendon In vitro Canine [87]
Flexor tendon In vitro Canine [85]
Flexor tendon In vitro Rabbit [95]
Patellar tendon In vitro Rat [68]
Supraspinatus tendon In vivo Rat [93]
BMP 12 Achilles tendon In vivo Rat [194]
BMP 2 Flexor tendon In vitro Canine [85]
Extensor tendon In vivo Canine [57]
Flexor tendon In vivo Rabbit [58]
Infraspintatus tendon In vivo Rabbit [59]
BMP 2, 7, 12 Infraspinatus tendon In vivo Sheep [94]
IGF Flexor tendon In vitro Rabbit [90]
Flexor tendon In vitro Rabbit [91]
Flexor tendon In vitro Rabbit [95]
Rotator cuff In vitro Rat [214]
PDGF Flexor tendon In vivo Canine [86]
Flexor tendon In vitro Canine [87]
Flexor tendon In vitro Canine [85]
Flexor and peroneal tendon In vitro Rabbit [88]
Flexor tendon In vitro Rabbit [95]
Patellar tendon In vitro Rat [64]
Rotator cuff In vitro Rat [214]
Rotator cuff In vivo Sheep [78]
Medial femuro-tibial ligament Iv vivo Rat [92]
TGFβ Patellar tendon In vivo Rabbit [80]
Achilles tendon In vivo Rat [76]
Flexor tendon In vitro Rabbit [82]
Flexor tendon In vitro Rabbit [69]
Flexor tendon In vivo/in vitro Rabbit [77]
Achilles tendon In vivo Rat [195]
Flexor tendon In vitro Rabbit [65]
Flexor tendon In vivo Rat [71]
Flexor tendon In vivo Murine [72]
TGFβ1 Flexor tendon In vitro Murine [73]
Flexor tendon In vivo Murine [74]
TGFβ1, 2, 3 Infraspinatus tendon In vivo Sheep [94]
VEGF Flexor tendon In vitro Canine [83]
Flexor tendon In vitro Canine [84]
Flexor tendon In vitro Canine [85]
Flexor tendon In vitro Rabbit [81]
ACS Achilles tendon In vivo Rat [98]
PRP Achilles tendon In vivo/In vitro Rat [96]
Flexor tendon In vitro Equine [99]
Flexor tendon In vivo Equine [97]
Review In vivo Human [105]
Review In vivo Human [106]
Review In vivo Human [109]
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expression of TGFβ1 mRNA [68]. Correspondingly, TGFβ1/3 receptor (CD
105; endoglin) expression was also found to be upregulated at the repair
site [69]. Juneja et al., found a biphasic pattern of TGFβ expression corre-
sponding to an early peak of TGFβ1 and a late peak of TGFβ3 expression
during healing [70]. Heisterbach et al., also found early and late peaks of
TGFβ1 expression [48]. However, there are also data indicating that
TGFβ1 provokes increased ﬁbrotic scar formation resulting in tendon
adhesions [71,72]. In a rabbit model adhesions were reduced using an
anti-TGFβ1 antibody, but were not further inﬂuenced by the addition of
an antibody against the isoform TGFβ2 [66]. Possibly an imbalance
between the TGFβ1-induced ECM-formation and tendon remodeling is
responsible for the formation of adhesions [73,74]. Thus, deﬁning the
appropriate doses and combinations of isoforms could be essential for
the successful application of TGFβ in tendon healing.
2.1.7. VEGF
Angiogenesis is important in both tendon degeneration, in cases of
impaired blood supply, and in regeneration, for which the best possible
capillary permeability is desirable [41]. VEGF promotes angiogenesis in
tendon healing [75], and its activity rises after the inﬂammatory phase,
especially during the proliferative and remodeling phases. In a canine
model of tendon transection, VEGF mRNA peaked 10 days after surgery
[76].
2.1.8. Effects of different growth factors on tendon healing
Based on the presence and inﬂuence of growth factors on tendon
healing a number of studies has been published with the aim of under-
standing the inﬂuence of growth factors on tendon biology in vitro and
on tendon healing in vivo (Table 1). For in vivo studies, the growth
factors can be applied by local injection, percutaneously or operatively,
or by implanting scaffolds or even suture material [77–79] containing
growth factors.
Growth factors are rapidly cleared following local injection, but their
persistencemay be prolonged using scaffolds or coated suture material.
There have been few investigations of growth factor release by coated
suture material and scaffolds in tendons, but there have been several
studies investigating the local application of growth factors. Local injec-
tion of TGFβ into the healing site of patellar tendons in rats signiﬁcantly
increased the load to failure [80]. Comparable resultswere found inﬂex-
or tendons of rabbit treated with VEGF, as long as the plantaris tendon
was preserved. In this study expression of TGFβwas signiﬁcantly elevat-
ed early in the healing course. It remains unclear whether the positive
effectwas caused by the VEGF therapy itself, the increased TGFβ expres-
sion provoked by VEGF, or both [81].
Interestingly native cells from different areas of the tendon tend to
react differently when treated with TGFβ. Type I collagen expression is
down-regulated and type III expression up-regulated in endotenon
cells compared to cells from the epitenon or the tendon sheath [82].
Possibly the up-regulation of collagen type III and the down-regulation
of collagen type I by cells in the endotenon marks the beginning of
tendon healing induced by TGFβ [81]. As well as differential expression
of collagens by epi- and endotenon cells, increasedmRNA expression for
VEGF was found at the healing site of ﬂexor tendons but not at the
epitenon [83,84]. Increased cell proliferation and collagen production
was also provoked by PDGF and bFGF. The effect was ampliﬁed by a
combination of both factors. In this study VEGF and BMP-2 did not
have the same positive effect [85]. Treatment with PDGF increased
total DNA, collagen crosslinking and hyaluronic acid content resulting
in improved functionalmovement, but did not improve the tensile prop-
erties of the healed tendon [86]. Combined treatment with bFGF and
PDGF increases ﬁbronectin deposition as part of the provisional matrix
and angiogenesis/revascularization in canine ﬂexor tenocytes [87].
Moreover PDGF stimulates the synthesis of proteoglycan, collagen,
non-collagenous protein and DNA [88]; bFGF was shown to accelerateintratendinous healing in patellar tendons [89]. Also IGF-1 stimulates
matrix synthesis and cell proliferation of tenocytes in vitro [90,91].
The positive effects of growth factors are not limited to intra-
tendinous lesions; PDGF increased failure load of the medial femuro-
tibial ligament [92] and several growth factors had a positive effect on
the tendon–bone healing site of the rotator cuff [93,94]. Combinations
of growth factors seemmore potent than individual growth factors de-
livered singly. For example, in an in vitro model using rabbit ﬂexor
digitorum tenocytes, the highest cell proliferation rates were achieved
by combining bFGF, IGF-1, and PDGF. The combination was effective at
lower doses than when the growth factors were delivered singly [95].
2.1.9. Autologous sources of growth factors
As noted above, it seems that the interaction of several different
growth factors is important in tendon healing. This could explain the
observed effectiveness of concentrates of autologous growth factors,
such as those containedwithin platelet rich plasma (PRP) or autologous
conditioned serum (ACS) [96–99]. In contrast to puriﬁed growth factors,
PRP has already been used clinically in patients with either tendinopathy
or tendon injury. Gosens et al., found signiﬁcant pain reduction in
36 patients with patellar tendinopathy after PRP injection [100]. In a
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reconstruction, PRP had a positive effect on donor site healing in the
harvested patellar tendon leading to pain reduction and smaller defect
size inMRI controls after 6months [101]. Moreover, the patellar tendon
graft itself seemed to remodel faster during ACL-reconstruction after
additional application of PRP [102]. In a rat Achilles tendon model
percutaneous administration of PRP 6 h after transection and resection
of 3 mm tendon resulted in an increased tendon callus and strength by
about 30% after 1 week, which persisted for as long as 3 weeks after
injection [96]. However, after surgery to repair acute Achilles tendon
rupture in patients Schepull et al., did not ﬁnd improvement in healing
after additional administration of PRP to the healing site [103]. In chronic
Achilles tendinopathy de Vos et al. failed to ﬁnd differences in pain or
activity level between patients treated with PRP or saline [104].
A later systematic review de Vos et al. found no evidence of efﬁcacy
using PRP to treat chronic lateral epicondylar tendinopathy [105]. Along
these lines, Hall et al. stated in their review on PRP entitled “platelet rich
placebo?” that the only reasonable use for PRPwas for therapy of refrac-
tory cases of lateral epicondylar tendinopathy, but not for other
tendinopathies or tendon repair [106]. However, because PRP is a vari-
able, poorly characterized cocktail of growth factors and other sub-
stances it is difﬁcult to draw strong conclusions.
Several different devices are approved by the FDA (U.S. Food and
Drug Administration) in the United States for generating PRP, resulting
in different compositions of growth factors and even cells (leucocytes
and erythrocytes). Moreover, PRP contains components other than
growth factors, including interleukins, chemokines, proteinases, inhibi-
tors of proteinases, adhesion molecules, sphingolipids, thromboxanes,
purine nucleotides, serotonin, calcium, and many other mediators. PRP
is considered to have anti-inﬂammatory properties, but some compo-
nents, such as IL-1, -6, and -8, are pyrogens [107,108]. Thus the precise
combinations and concentrations of the different factors within PRP are
important determinants of the properties of this autologous blood prod-
uct. This could explain the lack of activity described by Schepull et al.
[103] and de Vos et al. [104]. Prospective randomized controlled trials
using PRP formulations of standard, reproducible composition are need-
ed to determine whether PRP is useful in treatment of tendon disorders
[109].
2.2. Stem cells
Cell-based tissue engineering is one of the most attractive and widely
explored approaches for musculoskeletal regeneration. This strategy
relies on reparative cells, alone or in combination with biocompatible
scaffolds, which are delivered intra-operatively to the site of tissue
damage. Selecting the appropriate cell type is one of themost important
factors to be considered in such applications.
With regards to tendon engineering, several cell types, including
MSCs from different tissue sources (bone marrow (BM), adipose tissue
(AD), embryonic stem cells (ESCs), induced pluripotent stem (iPS) cells
and TSPCs) are suggested as suitable targets (reviewed in [110–115]).
2.2.1. BM-derived MSCs
MSCs for tendon tissue engineering canbe easily obtained froma BM
aspirate. Although they represent only 0.001–0.01% of the total cell pop-
ulation, they can be expanded to higher numbers in vitro [116]. When
appropriately stimulated, BM-MSCs can differentiate into various mes-
enchymal cell types, including osteoblasts, chondrocytes and adipocytes
[117]. Attempts to commit BM-MSCs to the tenogenic lineage have been
based on treatment with growth factors such as GDF-5 (BMP-14) and
GDF-7 (BMP-12) [118,119], or upon genetic transduction with BMP-2
and active SMAD8, BMP-12, BMP-13 or scleraxis cDNA [120–122].
Overall, these attempts have been moderately successful; although
the treated BM-MSCs adopted a tendon-like cell phenotype in vitro, it
is still unclear whether the phenotype remains stable when the cells
are implanted into a tendon lesion. One very attractive, potential featureof BM-MSCs is the possibility that they are hypoimmunogenic, therefore
allogeneic transplantation may not require immunosuppression; fur-
thermore they can exert immunomodulatory effects on various blood
cell types resulting in anti-inﬂammatory impact during tissue repair
[123]. It has been also suggested that these cells exercise in vivo potent
trophic and stimulatory functions on local progenitors, thus contributing
to tissue regeneration in this alternative manner, rather then differenti-
ating on site into tissue-speciﬁc cell types [124]. Possible difﬁculties
when using BM-MSCs for tissue repair include painful BM harvesting
procedures, lengthy periods for cell expansion, uncontrollable differen-
tiation in vivo into undesirable cell lineages and reduced qualities with
donor age [123].
In comparison to other tissue sources, BM-MSCs are the best studied
and characterized, and therefore themost frequently evaluated cell type
for the repair of tendon tissue [125]. The majority of the in vivo models
consist of partial or complete surgical transection or collagenase-
induced lesion of horse, rabbit or rat tendons. The tendon types that
are typically investigated includeAchilles, patellar and digitalﬂexor ten-
dons. A summary of relevant in vivo studies, based on BM-MSC therapy
of tendon injury, and their outcomes is given in Table 2. Taken together,
these studies demonstrated improved histological and biomechanical
properties of the tendon, indicating an increased rate of tendon healing
and maturation. However, in many of the models ectopic bone forma-
tion was described and when biomechanically tested, the regained ten-
don strengthwas approximately 20–60% that of an uninjured tendon. In
addition, only few studies have examined tendon healing after 6 weeks,
thus the long-term effects of therapy on tendon strength, functional
quality and performance or re-occurrence of the injury are unknown.
So far only few clinical trials have been conductedwith BM-MSCs for
therapy of tendons. Mazzocca et al. [126] isolated BM-MSCs from 11 pa-
tients during arthroscopic rotator cuff surgery. After cell expansion and
treatmentwith insulin, the authors showed that the BM-MSCs gain fea-
tures similar to those of tendon cells. In this study, however, the isolated
cells were investigated in vitro and no implantation in the injured
tendons was performed. Non-fractioned iliac-derived BMmononuclear
cells have been injected into tendinous lesions in 14 patients with com-
plete rotator cuff tear. After 12 months, the patients were evaluated
with the UCLA (University of California, Los Angeles) score and MRI,
both showing improved tendon healing and integrity. Only one patient
had deterioration of tendon strength and pain after 1 year [127]. Despite
the very preliminary nature of the above studies, the results suggested
that BM-derived cells can be isolated, stimulated towards the pheno-
type of tendon cells and introduced into tendon defects. However, the
tendon ﬁeld is in great need of carefully designed, pre-clinical studies
using large animal models aiming to: (1) monitor the fate of the im-
planted stem cells using different labeling techniques; (2) examine
cell dose-dependent effects; (3) evaluate tendon properties after longer
periods of times; and (4) standardize protocols and procedures, thus
allowing direct comparison between different studies. Subsequent to
this research, multicentre clinical trials can be initiated to validate the
true potential and optimal mode of application of stem cells for the
repair of human tendons. This approach is facilitated by the fact that
BM-MSCs are already approved for human use in graft versus host
disease, and are in a large number of human clinical trials for other indi-
cations. They are also used in veterinary medicine to treat several disor-
ders, including teninopathies.
2.2.2. AD-MSCs
Subcutaneous adipose tissue is a source of stem cells that are very
similar morphologically and molecularly to BM-MSCs. The AD-MSCs
are also multipotent; however they are less efﬁcient at osteogenic and
chondrogenic differentiation, but excel in adipogenesis compared to
BM-MSCs [128,129]. When treated with IGF-1 and TGFβ or GDF-5,
AD-MSCs upregulate the expression of tendon-related gene markers,
such as scleraxis and tenomodulin [55,130]. Kryger et al. [131] com-
pared AD-MSCs to tendon-derived cells and BM-MSCs, and found
Table 2
Tendon repair with bone marrow-derived MSC.
Tendon type Model Conclusion Reference
Achilles
tendon
Rat; surgical cut; MSCs cultured at hypoxic and normoxic conditions,
analysis at 2 and 4 weeks
Superior biomechanical testing in tendons treated with MSC cultured in
hypoxic conditions
[228]
Rat; surgical cut and enthesis destroyed; suture and MSC injection;
analysis at 15, 30 and 45 days
Improved healing and biomechanical properties; enthesis comparable
to control
[229]
Rat; surgical cut; total BM cell or MSC injection in DMEM;
analysis at 1, 2 and 3 weeks
Biomechanical properties of tendon treated with BM cells comparable
to normal
tendon; MSC second best
[230]
Rabbit; surgical transection; MSC-ﬁbrin; follow up at 1, 3,
6 and 12 weeks
At 3 weeks improved histological and biomechanical properties with no
difference at 12 weeks
[231]
Rabbit; surgical transection; knitted poly-lactide-co-glycolide scaffold
loaded with MSCs; analysis at 2, 4, 8 and 12 weeks
Higher rate of tissue formation and remodeling was observed early on
with restored function similar to native tendon
[232]
Rabbit; hallucis longus tendons transfered into calcaneal bone tunnel;
MSC treatment; analysis at 2, 4 and 6 weeks
Improved healing of the insertion of tendon to bone in the early stage [233]
Rabbit; surgical cut; MSCs in collagen gel; analysis at 12 weeks Constructs with lower cell density displayed superior biomechanical
properties
[234]
Rabbit; surgical transection; MSC-collagen implants; analysis at 4,
8 and 12 weeks
Improved collagen organization and increased load properties [158]
Patellar
tendon
Rat; surgical transection; MSCs with ﬁbrin injection; analysis at 10
and 20 days
Biomechanical properties were not signiﬁcantly improved but tendons
displayed
more mature organization without ectopic ossiﬁcation
[235]
Rat; surgical full thickness window defect; MSCs with ﬁbrin injection;
analysis at 10 and 20 days
More dense collagen ﬁbers, higher cellularity and matrix without ectopic
ossiﬁcation were observed
[236]
Rabbit; surgical cut; MSCs in dog decellularized tendon composites;
analysis at 2 weeks
MSC survived in multilayer composite and expressed tendon phenotype [173]
Rabbit; surgical cut; MSCs in a gel-sponge composite;
analysis at 12 weeks
Superior cellular alignment, but maximum force and stress compared to
gel only
[237]
Rabbit; surgical defect; MSCs from young and aged rabbits in collagen
I gels; analysis at 12 weeks
No signiﬁcant difference in biomechanical properties of tendons treated
with young or aged MSC
[238]
Rabbit; surgical cut; implanted MSCs; analysis at 2, 3, 5 and 8 weeks MSC survived and differentiated into tendon-like spindle cells [239]
Rabbit; surgical cut; MSC-collagen implants; analysis at 6,
12 and 26 weeks
Ectopic ossiﬁcation developed in approx. 25% of the tendons with
MSC-collagen implant; no signiﬁcant differences in mechanical
properties across different seeding densities
[159]
Rabbit; surgical cut; MSCs in collagen gel; analysis at 4 weeks Better biomechanical properties but no signiﬁcant improvement of
tendon microstructure
[240]
Superﬁcial
digital
ﬂexor
tendon
Horse; naturally-occurring tendon injury; MSCs with marrow
supernatant; analysis at 6 months
Treated group exhibited normalization on a biochemical, morphological
and compositional level
[241]
Horse; collagenase-induced tendinitis lesion; MSC injection;
analysis at 8 weeks
Increased tensile stiffness in MSC-treated group, but similar histological
scores to controls without MSC
[217]
Horse; collagenase-induced tendinitis lesion; MSC injection Repaired tendon architecture comparable to healthy tendon [242]
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suggesting AD-MSCs as alternative cell type for tendon tissue repair.
When injected into horse superﬁcial digital ﬂexor tendons with
collagenase-induced tendinitis, AD-MSCs improved collagen ﬁber orga-
nization and overall tendon structure [132]. Increased yield loads and
energy absorption were described in a rabbit injury model of deep
digital ﬂexor tendons treated with AD-MSCs [133]. In sum, AD-MSCs
are widely available, multipotent cells that are simple to obtain without
high morbidity, and represent an attractive source of cells for tendon
tissue engineering. Nevertheless, there has been little exploration of
using AD-MSCs for tendon therapy [134]. Amajor difﬁculty is to restrict
AD-MSC differentiation within the tendon defect site to the tendon cell
lineage, avoiding their indigenous preference towards forming adipo-
cytes. Nevertheless, the risk of heterotopic ossiﬁcation should be less
than when using BM-MSCs [134]. Like BM-MSCs, AD-MSCs are already
in clinical trials for other indications.
2.2.3. ESCs and iPS cells
ESCs constitute the inner cell mass of blastocysts and are able to pro-
duce all different cell lineages from the three germ layers [135]. Unlike
MSCs, they can be passaged indeﬁnitely. Therefore in various tissue
and organ regenerative models, including cardiovascular, neuronal
and pancreatic repair, ESCs have considerable advantages [135]. Despite
some clear beneﬁts of ESCs over adult stem cells, their application raises
social and moral issues regarding disassembly of embryonal tissues
[135]. Other obstacles that have to be resolvedwhen using ESCs include
teratoma formation and spontaneous differentiation. Therefore, in the
recent years iPS cells, generated by genetic reprogramming of adult
lineage committed cells, have been suggested as alternatives to ESCs[136]. These cell types have overlapping characteristics and yet iPS
cells can overcomemany current ethical concerns in ESC-based therapy.
So far ESCs and iPS cells have not been extensively studied for tendon
repair due to the lack of protocols to differentiate these cells into the ten-
don lineage. Non-differentiated ESCs have been injected in horse tendon
lesions 1 week after collagenase-induced tendonitis, and histology and
ultrasound analyses demonstrated improved lesion size [137]. Guest
et al., [138] directly compared the survival of ESCs to MSCs after implan-
tation into surgically created tendon defects in the horse. Interestingly,
ESCs were detectable up to 90 days post operatively, while less then
ﬁve percent of MSCs survived. However, in these studies it remains
unclear if ESCs successfully differentiated into tendon progenitors. Chen
et al. [139] were the ﬁrst to propose stepwise differentiation of human
ESCs into tenocytes via an MSC intermediate step. Cell sheets of ESC-
derived MSCs were engineered into tendon-like layers under static me-
chanical load in vitro and used to repair a window defect in the patellar
tendon. The implanted cells were detectable at least 4 weeks after sur-
gery, and the ESC-MSC-treated tendons were larger than the controls
and contained continuous collagen ﬁbers and cells resembling tenocytes.
Importantly, because of the stepwise differentiation procedure, the risk of
teratoma formation is greatly reduced and, indeed, was not observed
in vivo.
A study by Xu et al. [140], was the ﬁrst to report a positive effect of
human iPS cell-derived neural crest stem cells combined with a ﬁbrin
gel on the healing of rat patellar tendon window defects. Histological
and mechanical analyses demonstrated improved matrix synthesis
and superior mechanical properties of defects treated with iPS cells. In-
terestingly, the authors also found that the transplanted cells produced
fetal tendon-related matrix proteins, stem cell recruitment factors, and
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repair process. The above results suggest that ESCs and, presumably
iPS cells, can be applied safely in tendon regeneration after controlling
their differentiation pathway.
2.2.4. Tendon-derived cells
Although knowledge of the differentiated cells resident in the
tendon tissue has increased, still little is known about their precursors.
Furthermore, the ﬁeld is still lacking clear terminology on the different
subsets of tendon cells. This is mostly due to difﬁculties to purify, expand,
maintain and compare populations of pure stem cells, progenitors,
tenoblasts and tenocytes. For this reasonwe have given this section a uni-
fying title.
Stem/progenitor cells of mesenchymal origin are of great interest in
understanding tendon development and the healing processes. As
mentioned previously, Bi et al., [27] demonstrated that human and
mouse tendons harbor an unique cell population that has both stem cell
but also tendon-speciﬁc characteristics. For example, these tendon-
derived cells expressedhigh levels of scleraxis, cartilage oligomericmatrix
protein (COMP), tenascin-C and tenomodulin, all tendon-related factors.
Because the cells of this population showed heterogeneity in their stem
cell properties, the authors named them tendon stem/progenitor cells
(TSPC). When compared to BM-derived MSCs, TSPC were closely related,
but not identical in terms of molecular marker proﬁle and in vivo behav-
ior. When the cells were applied in vivo, TSPC formed tendon- and
enthesis-like structures, whereas BM-MSC formed bone- and BM-like
structures. However, in this study, the cells were not used in a clinically
related, tendon defectmodel. In addition, this study showed that TSPC re-
side within a unique niche, where the two extracellular proteoglycans
biglycan and ﬁbromodulin control their functions by modulating BMP
signaling.
The double knockout of these two proteoglycans is characterized by
higher tendon cellularity together with decreased collagen ﬁbril thick-
ness. TSPC isolated from these mice had augmented clonogenicity and
cell proliferation, but reduced collagen type I and scleraxis expression.
Lastly, Bi et al. [27] were the ﬁrst to show that there is a link between
distorted TSPC functions and tendon pathology, since TSPCs within the
biglycan/ﬁbromodulin-deﬁcient tendonnichewere farmore responsive
to BMP signaling, leading to TSPC favoring the osteogenic lineage. In
turn, this resulted in so-called in-tendon ossiﬁcation. Thus, the above
data suggest that the molecular environment provided by the niche is
essential for the correct maintenance and differentiation of the stem/
progenitor cells during tendon development and repair.
Studies by Tempfer et al., [28] andKohler et al., [29] also demonstrated
the existence of a TSPC population within human supraspinatus and
Achilles tendons, respectively. Several articles have suggested that
tendon-derived stem cells (TDSC) can be isolated, expanded and eventu-
ally used in regenerative strategies (reviewed in [141,142]). Puriﬁcation
and expansion of a cell population containing only TDSCs is still difﬁcult,
because we lack molecular markers discriminating the discrete steps of
tendon cell lineage differentiation from primitive stem cells via progeni-
tors to mature tenocytes, as well as the incomplete differentiation of the
primary cells. Because of this, we have used in the text the term TSPC.
In order to unite and validate the existing data, the tendon ﬁeld urgently
requires: (1) to standardize the protocols for TSPC enrichment; (2) to de-
velop appropriatemethods to separate stemcells fromprogenitors; (3) to
establish efﬁcient methods for achieving terminal tenogenic differentia-
tion in vitro which will permit validation of TSPC properties; and (4) to
determine if TSPC differentiation in vitro reﬂects their differentiation
capacity in vivo.
The discovery of TSPCs had a major impact in the ﬁeld, since TSPCs
might be involved in tendon tissue homeostasis and repair; alternatively,
they can be used for practical purposes in tissue engineering strategies for
injured tendons. Still, there remains the need to clarifywhether embryon-
ic tendonprogenitors andTSPCs are identical cell populations aswell as to
generate solid data concerning TSPC location and function in vivo.Tempfer et al., [28] have shown that cells expressing simultaneously
tendon and pericyte-associated marker genes are localized to the
perivascular space of tendon tissue, hence suggesting that this niche
might be the source of local stem/progenitor cells. Still, tendons are poorly
vascularized, hence the contribution of perivascular cells to the regulation
of tendon cell fate and functionsmight be less pronounced than in tissues
with high blood supply. Interestingly, Mienaltowski et al., [36] reported
the existence of two different stem/progenitor populations within the
peritenon and tendon proper of mouse Achilles tendons. More studies
are required to reconstitute carefully the regional cell composition of ten-
dons and the interconnections between different cell types. Improving
our knowledge on the above questions can provide novel, fundamental
understanding not only of the development of tendon tissues, but also
of their sustainability and repair.
In terms of practical application, there are several challenging issues to
solve prior the use of tendon-derived cells for tendon repair. Allogeneic
cells may lead to an immune reaction, whereas autologous tendon-
derived cells will avoid immune complications, but may lead to a co-
morbid state in the patient. Furthermore, during in vitro expansion,
tendon-derived cells may undergo phenotypic drift. Yao et al., [143]
have shown in human tendon cells that the ratio between collagen III
and I increases with progressive passaging, while decorin expression
signiﬁcantly decreases. Schulze-Tanzil et al., [144] suggested that the dif-
ferentiated state could be preserved if the cells are grown in three-
dimensional pellets. A combination of ultrastructural, biochemical and
molecular analysis indeed demonstrated that the phenotypic identity of
the tendon-derived cells was retained when the cells were cultured in
this fashion [144]. Therefore, it will be important to establish in vitro
culture systems, based on three dimensional cultivation or by using
mechanical strain, which can support unaltered TSPC identity over longer
periods of time.
To date, only few studies have used tendon-derived cells in tendon
repairmodels. Cao et al., [145], used autologous tenocytes to bridge ten-
don partial defects in hens and observed 14 weeks postoperatively that
the engineered tendons displayed histologically a structure very similar
to that of normal tendons. Similar conclusions were reached by Chen
et al., [146] after introducing autologous patellar tenocytes cultured on
porcine bioscaffolds intomassive rabbit rotator cuff defects and analyzing
tissue regeneration at 4 and 8weeks. The authors concluded that implan-
tation of tenocyte-loaded scaffolds results in superior tendon healing
when compared to the control group receiving only scaffold. However,
autograft tendon controls were still better then the engineered tenocyte
constructs, suggesting that further optimization of the technology is
required. Stoll et al., [147] investigated the healing of a partial Achilles ten-
don in the rabbit after ﬁlling defects with Achilles tenocytes loaded onto
polyglycolic acid (PGA)/ﬁbrin scaffolds. The authors generated novel
scoring systems for macroscopic, histological and elastic ﬁber assessment
of the progress of tissue repair. Although no clear advantage of the
tenocyte-scaffold group was detected at 6 and 12 weeks post operation,
this study provides a useful multifaceted scoring system for characteriza-
tion and cross-study comparison of tendon healing models.
Tenocyte-based regeneration of full size Achilles tendon defects in rats
has been compared to that based on BM-MSCs [148]. For bridging the de-
fect ends, PGA and collagen type I scaffolds seeded with one or the other
cell type were used and ﬁxed with a frame suture. After 16 weeks, DNA
from the implanted cells was detected in the regenerated tissue, consis-
tentwith their long-term survival. Despite evidence of central ossiﬁcation
in all study groups, biomechanical tests revealed that samples loaded
with tenocytes had signiﬁcantly better failure strength/cross-section ra-
tios compared to defects receiving BM-MSCs or inseeded scaffolds. Ni
et al., [149], were the ﬁrst to describe histologically, biomechanically
and ultrasonographically that TSPCs can improve the repair of a rat patel-
lar tendonwindow defect. No ectopic bone formationwas detected up to
4 weeks post-injury. How implanted tendon-derived cells inﬂuence local
cells at the site of tendon damage is unclear and needs further clariﬁca-
tion. More studies are also required to understand the fate and long-
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the beneﬁts of using these cells rather than MSCs from different sources.
Themain advantage of tendon-derived cells is that, being native in origin,
when re-implanted into tendon defects, they will better accommodate to
familiar environment and are likely to survive longer and differentiate
more easily into terminal tenocytes.
Taken together, this area holds much promise for tendon therapy
after clarifyingmanyopen questions. Itwill be of great importance to in-
vestigate further the identity, genetic marker proﬁle, localization and
in vivo functions of TSPCs as well as to carry out well-designed pre-
clinical experiments to determine the role of TSPCs during the progres-
sion of tendon diseases and subsequent repair processes.
2.2.5. Unresolved issues in cell-based therapy for tendons
The involvement of each of the above cell types has to address a
number of important challenges, such as determining: the amount of
cells needed;whether combinationwith growth factors or geneticmod-
iﬁcation is helpful and, if so, which growth factors or genes to use;
which scaffolds, if any, to use; the optimum time point of delivery. To
deﬁne the ideal cell number, dose-dependent in vivo studies will be im-
portant. Most likely the optimal number of cells will vary relative to the
size of the tendon defect, the type of cell type used and the particular
tendon in need of repair. Therefore, it is necessary in forthcoming
research to deﬁne and understand the exact mechanisms underlying
the in vivo performance of different cell types. Crucial questions in-
clude: do the implanted cells provide trophic support and stimulate
local progenitors or do they commit on-site into the tenogenic lineage?
A useful approach to address such questions will be to develop or em-
ploy strategies to label and track the implanted cells during the different
healing stages. In addition to determining the optimal ratio of implanted
cells to defect dimensions, the ﬁeld has to resolve how to obtain and
multiply in a short time frame the required amount of stem cells, with-
out harming their innate ability to differentiate or causing uncontrolled
differentiation. Co-delivery of stem cells with growth factors or using
genetically altered stem cells can enhance their qualities and navigate
them quicker and more effectively into the preferred differentiation
cascade. However, such manipulations could have poorly controlled
side effects on local stem and progenitor cell populations.
The seeding of the stemcells onto differentmatrices can improve their
maintenance and ampliﬁcation at the site of tendon injury. Furthermore,
the topography andmechanical properties of the carriers can be designed
in a way to direct stem cell differentiation towards tendon progenitors or
even mature tenocytes. The precise timing of stem cell delivery can be
determined by the cell type and carrier combination. For example,
whenMSCs are to be used, implantation can take place already at the in-
ﬂammatory stage since this cell typemight exert a beneﬁcial effect bypar-
ticipating in immunomodulation, reducing inﬂammation and stimulating
local stem cells and tenoblasts.When tendon-derived cells are to be used,
it might be more appropriate to introduce them at the later, proliferative
stage when they can speed the endogenous healing process.
With regards to the timing of the complete procedure the following
factors should be considered: (1) hospitalization time of the patient;
(2) time to obtain, enrich and multiply the cells; (3) if the cells are mod-
iﬁed or stimulated, the time necessary to carry out such procedures; (4) if
the cells are applied in combination with biomaterials, the time for
scaffold loading and cell adhesion. Ideal protocols should contain only a
few short steps. For example, one way to speed up the preparation will
be to purify the reparative cells from the primary cell milieu with cell-
speciﬁc surface antigens. Finally, stem cells of autologous, allogenic or
xenogenic nature should be compared. Each of these variants holds ad-
vantages and disadvantages. In autologous applications, it is important
to determine donor site morbidity and the ﬁtness of the stem cells since
tissue aging or pathology can distort stem cell functions. Recent investiga-
tions focusing on BM-MSC demonstrated apparent age-related changes
such as a reduced proliferation and clonogenicity aswell as altered differ-
entiation potential [150,151]. Baxter et al., [152] observed rapid telomereshortening and earlier entry into growth arrest and senescence; Kasper
et al., additionally found reduced antioxidant defense, altered cytoskele-
ton organization and lower migratory capacity of aged BM-MSCs [153].
We have recently reported that human TSPCs fromaged anddegenerated
tendons have signiﬁcantly reduced proliferation capacity and premature
entry into senescence, decelerated motion and delayed wound closure
due to dysfunctional actin dynamics [29]. Hence, similar to other tissues,
aging and disease exhaust the local stem cell pool in terms of size and
functional ﬁtness. Therefore, when such autologous cells are candidates
for use in tendon repair in aged individuals, various possibilities to correct
their endogenous deﬁcits or to pre-activate them ex vivo or in situ via
growth factor stimulation or gene therapy have to be carefully considered
[154]. The development of suitable allograft donor cells would obviate
many of these problems. However, the use of allogenic cells can also be
associated with difﬁculties such as obtaining sufﬁcient donor material,
donor background diseases, prolonged storage of the cells and a possible
deterioration of cell quality during storage. Onemajor advantage of xeno-
graft cells is that they can be available in large numbers and ready for use
at anymoment. However, their use is limitedwhile possible zoonotic dis-
eases and xenograft reactions have to be considered and addressed.
2.3. Biomaterials
Currently, tendon repair involves the use of autologous or allogeneic
tendon transfer, which can restore tendon function in the affected area.
However, both options have drawbacks, the ﬁrst related to donor site
morbidity and the second to risk of immune rejection. In addition, rarely
does the transferred tendonmaterialmatch the tensile properties of the
repaired tissue. Therefore, a number of biomaterials have been explored
as alternatives to tendon transfer for tendon tissue engineering
(reviewed in [155,156]). Some of these materials have been borrowed
from the neighboring ﬁelds of cartilage and bone tissue engineering,
and some have been speciﬁcally designed to resemble as close as possible
the structural and biomechanical features of native tendon tissue. The
ideal scaffold should cover a number of requirements such as: (1) to be
biocompatible; (2) to support cell attachment and growth; (3) to have
high surface area; (4) to promote tenogenic differentiation pathway;
(5) not to induce host inﬂammatory responses; (6) when not biodegrad-
able, tomimic native tendon architecture andmechanical properties. Fur-
thermore, the scaffold should be easily reproducible, scalable, have good
storage properties and, ideally, able to be customized.
Natural biomaterials include: collagen; silk; ﬁbrin; hyaluronic acid;
elastin; alginate; chitosan; porcine small intestine submucosa (SIS);
human, porcine or bovine dermis; and decellularized tendon xenografts
[155–157]. Most biomaterial studies have investigated how MSCs or
tendon-derived cells respond to these materials in terms of cell adhe-
sion, cell proliferation and survival over time, gene expression and dif-
ferentiation [155–157]. Some of the studies have taken a step further
into in vivo testing of the materials, alone or in combination with cells,
and have examined host tissue reactions or tendon healing process
(refer also to [115,157]). Some examples of studies on collagen-based
scaffolds and xenografts will be discussed here.
2.3.1. Collagen-based materials
Collagen gels and composites, most frequently loadedwith BM-MSCs,
have been used for repair of different tendon gap models, as indicated in
Table 1. In the articles of Young et al., [158] and Awad et al., [159] exper-
imental groups treated with cell/gel implants achieved higher strength
compared to suture-only controls. Interestingly, in the second study no
additional beneﬁt of increasing cell density in the collagen type I gel
was found [159]. Another study showed that reducing cell to collagen
ratio by 20-fold actually improved cell viability, lowered the degree of
ectopic bone formation and enhanced the biomechanical properties of
patellar tendon 12 weeks post-operatively [160]. It was suggested that
material implants should exhibit physical properties similar to normal
tendon tissue, but should be degradable. This would allow support and
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also replacement of the scaffold over time during de novo production of
tendon matrix [160].
As mentioned earlier, critical design criteria for the ideal tendon
graft requires the material to exhibit the mechanical properties of
normal tendon, to facilitate functional integration and also to promote
native tendon regeneration. Nanotechnology-based approaches allow
development of various biomimetic scaffolds such as nanoﬁbers and
nanocomposites. Speciﬁcally, aligned nanoﬁbers from collagen type I
hold advantages because of their potential tomimic thematrix architec-
ture of native tendon and, in turn, to regulate cellular responses. In vitro
studies with cell-loaded aligned collagen I [161,162] convincingly
showed that the aligned scaffold topography can induce a cell morphol-
ogy similar to that of tenocytes, achieve matrix alignment and promote
the upregulation of tendon-related genes such as scleraxis and collagen
type XIV. Furthermore, the in vivo investigation by Kishor et al., [161]
reported that braided, aligned collagen type I ﬁbers introduced in longi-
tudinally incised rabbit patellar tendons undergo limited degradation
and associate with a low-grade granulomatous inﬂammation. Addition-
ally, quantitative histology revealed that the cross-sectional areas of
tendons treated with the aligned scaffolds were larger and stiffer than
controls. In sum, the above studies suggested that aligned nanoﬁbers
are superior to randomly oriented biomaterials, because they are bio-
compatible and, moreover, can stimulate the implanted cells to differ-
entiate towards the favorable tenogenic lineage. Thus they have the
potential to be used as carriers for tendon tissue engineering applica-
tions. One critical limitation of these scaffolds is scale-up to dimensions
relevant for the repair of human tendon.
2.3.2. Xenografts
A possible way to overcome the difﬁculty of generating stable scaf-
folds in large sizes is to use xenograft tissues which have matching
and customized proportions similar to those of human tendon defects.
FDA-approved porcine SIS devices (Restore and CuffPatch) have been
used in a number of laboratory studies of rotator cuff and Achilles
tendon injury models performed in dog [163–165], rabbit [166] and
rat [167]. Although the properties of healthy tendon were not fully
restored, the studies reported positive histological and mechanical out-
comes in comparison to non-treated defects. Furthermore, upon analyz-
ing SIS degradation patterns, it was found that SIS is subjected to rapid
degradation in the ﬁrst 4 weeks after surgery, which suggests that it
can serve as a temporary scaffold for quick cellular inﬁltration [165].
Following these encouraging results, multiple clinical studies were con-
ductedwith patients undergoing rotator cuff or Achilles tendon surgery
(reviewed in [155]). Earlier investigation suggested successful tendon
reconstruction with SIS devices in 11 out of 12 patients up to 2 years
after the surgery [168]. However, subsequent investigations found
that SIS-treated groups had no augmented properties and that SIS incor-
poration did not improve the rate of tendon healing [169–171]. The rea-
sons for this discrepancy are not entirely clear and the major side effect
reported in the above studies was a non-infectious effusion.
Decellularized tendon, of allograft or xenograft origin, is another tissue
with promise for tendon repair. This application consists of harvesting
tendon pieces from cadavers or animals which, after decellularization
and slicing, are re-seeded with BM-MSCs, and ﬁnally packaged together
into a single scaffold. Interestingly, when cultivated on such matrices,
BM-MSCs exhibit a phenotype resembling tendon cells, suggesting yet
again that the appropriate nano-topography and stiffness can enforce lin-
eagedifferentiation [172–174]. It is logical to conclude that the best choice
for tendon repair is tendon or ligament ECM; however, there are several
unresolved difﬁculties with the use of decellularized tendon scaffolds,
such as the poor cell repopulation of the deeper tendon layers and the ob-
servation that the decellularization procedure reduces the mechanical
properties of the grafts.
Scaffolds derived from human cadaver (GraftJacket), bovine
(TissueMend and Bio-Blanket) and porcine dermis (Permacol) have arich collageneous matrix, retain native dermal ECM architecture and
vascular channels, and have been approved by FDA for the reinforce-
ment of soft tissues. More than a few studies have shown their efﬁcacy
in rotator cuff and Achilles tendon repair. For example, Adams et al.,
[175] studied the use of human cadaver dermis in a canine infraspinatus
injury model and found robust tendonous tissue formation at the site of
scaffold implantation after 6 months. Bond et al., [176] reported im-
proved shoulder mobility and decreased pain after implantation of
human dermis in patients with rotator cuff tears. Positive outcomes
after applying human dermis in the repair of large rotator cuff defects
were also documented by Rotini et al., [177] and Snyder et al., [178].
The healing effect of human dermis materials on Achilles tendon rup-
tures was shown in a series of clinical studies published by Lee et al.,
[179] and Lee et al., [180]. Early return to physical activity, improved
foot strength, reduced chronic pain and no re-ruptures were observed
up to 30months after surgery. Interestingly, Valentin et al., [181] exam-
ined histologically the host tissue response to porcine SIS and human,
bovine and porcine dermis devices in a rodent model. The authors
found that each biomaterial leads to a distinct form of tissue remodeling
in terms of cellularity, vessels, inﬂammation and matrix organization.
Interestingly, xenograft dermis scaffolds degraded slowly and were
associated with higher inﬂammatory score and accumulation of denser
and less organized ﬁbrous tissue. Therefore, future controlled compari-
son studies are necessary to clearly deﬁne the advantages and limitation
of each biomaterial.
In conclusion, natural biomaterials show signiﬁcant promise for
enhancing tendon repair especially in combination with reparative
cells. At present, the tendon ﬁeld still lacks classical biologics or
tendon-speciﬁc drugs to aid repair. Therefore biomaterials, especially
scaffoldsmimicking native tendon architecture, represent a smart alter-
native option to solve one of the major problems of the ﬁeld, namely to
drive the reparative cells into the appropriate tendon cell lineage. How-
ever, the available data do not permit deﬁnitive conclusions, and often
the use of identical materials, for example dermis scaffolds, produces
variable results between different studies [175,181]. Thus,more investi-
gations are required to improve and standardize the properties of bio-
materials and to evaluate their role in the clinical practice of tendon
repair.
2.4. Gene therapy
2.4.1. Concepts
It has been recognized for a long time that gene therapy has the
potential to promote the repair and regeneration of damaged tissues,
including tendons [182–185]. In this context, gene transfer is not used
to compensate for a deﬁned genetic defect, but instead to serve as a
biological delivery system for the encoded gene products.
Gene transfer holds many advantages over traditional methods for
delivering biologicals to sites of injury. In particular, it allows the local,
focal production of gene products within and around the lesion in a
sustained and potentially regulated fashion. Moreover, proteins synthe-
sized locally as a result of gene transfer are likely to have undergone
authentic post-translational processing leading to greater biological ac-
tivity and a reduced risk of triggering neutralizing immune reactions.
Gene transfer is particularly useful for delivering gene products with
an intracellular site of action, including non-coding RNA molecules,
signaling molecules and transcription factors; SMAD8 and scleraxis
are relevant examples of the last two [120,122].
2.4.2. Vectors
Vectors are used to transfer genes (usually cDNAs) to target cells. Be-
cause viruses are naturally able to transfer with high efﬁciency their
genes to the cells they infect, they have been widely used as vectors.
For this purpose, the viral genome is manipulated to remove sequences
required for replication and virulence, while retaining those needed for
infectivity. (The ability to replicate is retained in certain cancer gene
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space generated by these manipulations to produce a viral vector that,
in principle, can infect a target cell and deliver its genetic payload to
the nucleus without replicating or causing adverse events.
Recombinant viruses so far studied experimentally for gene delivery
to tendons and ligaments include adenovirus, lentivirus, retrovirus,
adeno-associated virus (AAV). The main properties of these four
vectors are compared in Table 3, bearing inmind that themanymodiﬁ-
cations made progressively to these vectors make simple generaliza-
tions increasingly difﬁcult. Gene transfer with a viral vector is known
as transduction.
Because clinical grade viral vectors are expensive and complicated,
there is continuing interest in non-viral vectors for gene delivery.
These raise less safety issues, are usually simpler to manufacture, have
less restrictions in carrying capacity, often lower immunogenicity and
should make quicker progress through the regulatory process for
human use. Non-viral vectors can be as simple as naked, plasmid DNA.
Often, the efﬁciency of gene transfer is improved by combining the
DNA with a polymeric carrier or by using a physical stimulus such as
electroporation. Non-viral gene transfer is known as transfection.
The properties of viral and non-viral vectors used in regenerative or-
thopedics have been reviewed in several recent publications (refer to
[186–188]).
2.4.3. Strategies
Regardless of the vector, there are two general gene delivery strate-
gies, in vivo and ex vivo. For in vivo delivery, the vector is introduced
directly into the body by injection or other form of direct application. Be-
cause the cellularity of tendon is low, in vivo administration in this way
should not lead to high levels of transgene expression. Nevertheless,
there exist several examples of its successful application in animalmodels
of tendon healing (Table 4).
An alternative in vivo application strategy uses a scaffold impregnated
with vector; this is known as a gene-activated matrix (GAM). This con-
cept has been applied to tendons by associating adenovirus vectors with
a gelatin sponge [189] and by using allograft tendon as a scaffold for
AAV in a process known as “allograft revitalization” [190].
During ex vivo delivery, cells are genetically modiﬁed outside the
body and then injected or otherwise implanted at the appropriate site.
Ex vivo delivery combines gene therapywith cell therapy and is increas-
ingly popular when progenitor cells, such as MSCs, are used.
Although the methods of in vivo gene delivery are simpler than
ex vivo delivery, the latter is presumed to be safer because viruses are
not introduced directly into the body. Because the recombinant viruses
used for this type of gene therapy cannot replicate, the cells that carryTable 3
Salient properties of vectors used in experimental studies of tendon healing.
Vector Key properties Advantages Disad
Adenovirus Non-integrating
Multiple serotypes
Double stranded
DNA genome
Straightforward
production
Efﬁcient
Transduces non-dividing
cells
Wide host range
Inﬂam
Antig
Adeno-Associated
Virus
Recombinant AAV is
non-integrating
Wild-type AAV has single
stranded DNA genome
Multiple serotypes
Transduces non-dividing
cells
Wild-type AAV causes no
known disease
Non-inﬂammatory
Difﬁc
Small
Retrovirus RNA genome
Integrating
Straightforward to produce
Amphotropic virus has
wide host range
Trans
Risk o
Lentivirus RNA genome
Wild-type virus is integrating
Transduces non-dividing
cells
Very high levels of
transgene expression
Risk o
non-ithem do not shed infectious particles. It can, however, be argued that
the cells used in ex vivo gene delivery may have been cultured in
media containing xenogeneic components, thereby introducing an ele-
ment of risk, although the same would be true of ex vivo cell therapy in
general.
Also, as noted, ex vivo gene delivery offers the possibility to combine
the power of cell therapy with that of gene therapy. However, clinical
application of such an approach is constrained by the present need to
use autologous cells, which makes the process expensive and cumber-
some. Development of suitable allogeneic cell lines for this purpose
would greatly expedite the process.
To expedite ex vivo delivery, there is interest in developing technol-
ogies where suitable tissues that harbor accessible progenitor cells are
harvested, genetically modiﬁed and reimplanted during one surgery
[191,192]. Using a technique that was ﬁrst developed for bone healing
[193] geneticallymodiﬁedmuscle grafts have been employed for tendon
healing in animal models [194,195].
Although regulated transgene expression has not yet been explored
in the context of tendon gene therapy, the availability of inducible
promoters allows consideration of this approach. This reﬂects the likeli-
hood that optimal healingmay require the level of transgene expression
to vary during the healing process. Also, such promoters allow the
theoretical possibility of expressing one or more genes at different
times from a polycistronic vector.
2.4.4. Progress
Early experiments conﬁrmed the ability of various viral [196–199] and
non-viral vectors [200–203] to deliver marker genes to ligaments and
tendons by in vivo and ex vivo means. This work has been comprehen-
sively reviewed by Hildebrand et al., [204]. Once marker gene delivery
was achieved, it became possible to investigate the results of transferring
genes with therapeutic potential.
As summarized in Table 4, most published studies using animal
models of tendon repair have taken the approach of delivering a growth
factor, especially one expected to promote the differentiation of progen-
itor cells into tenocytes. Promising results have been reported with
BMP-12/GDF-7 [194,205] and BMP-14/GDF-5 [190,206,207], but not
BMP-13/GDF-6 [208], even though all three of these induce tenogenesis
in other systems [56,209] and BMP-13 gene transfer to MSCs induces
ligamentogenesis in vitro [121]. It is possible thatmechanical factors ac-
count for this discrepancy [210]. Transfer of scleraxis has been shown to
promote the differentiation of MSCs into tenocytes in vitro [122] and,
when used ex vivo with MSCs, to enhance healing of the rotator cuff
in a rat model [211]. Similar results were reported using a combination
of BMP-2 and SMAD8 cDNAs to promote tenogenesis [120].vantages Comment
matory
enic
Widely used in clinical trials
One well publicized death
ult to produce
carrying capacity
Possible to engineer AAV with double
stranded DNA genome
Increasingly popular for clinical trials
because of safety
duction requires host cell division
f insertional mutagenesis
Usually used in ex vivo gene delivery
Has been widely used in clinical trials
Insertional mutagenesis has caused
leukemia
f insertional mutagenesis, but
ntegrating vectors developed
Increasing use in clinical trials
Table 4
Use of gene transfer to promote tenogenesis in animal models of tendon injury.
Gene Vector Delivery mode Animal model Reference
BMP-14/GDF-5 Adenovirus In vivo Rat, Achilles [206]
Adenovirus In vivo Rat, Achilles [207]
AAV In vivo Mouse, ﬂexor tendon [190]
BMP-13/GDF-6 Adenovirus Ex vivo/MSC Rat, rotator cuff [208]
BMP-12/GDF-7 Adenovirus In vivo Chick, ﬂexor tendon [205]
Adenovirus Ex vivo/muscle Rat, Achilles [194]
TGFβ, VEGF Adenovirus Ex vivo/MSC Rabbit, Achilles [213]
TGFβ Adenovirus Ex vivo/muscle Rat, Achilles [195]
Scleraxis Adenovirus Ex vivo/MSC Rat, superspinatus [211]
SMAD8, BMP-2 Liposome Ex vivo/MSC Rat, Achilles [120]
bFGF AAV In vivo Chick, ﬂexor tendon [212]
PDGF-B Liposome In vivo Rat, patellar tendon [215]
Nanoparticle In vivo Rat, Achilles Tendon [243]
Retrovirus Ex vivo/tendon
ﬁbroblasts
Rat, rotator cuff [214]
Interleukin-10 Lentivirus In vivo Mouse, patellar
tendon
[216]
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that are not speciﬁcally associated with differentiation of tenocytes, but
whichmay enhance cellularity, vascularity or the deposition of extracel-
lular matrix. Examples include TGFβ [195], bFGF [212], VEGF [213] and
PDGF-B [214,215]. In general, the results have been encouraging.
Because repair and regeneration are progressive,multi-step processes,
there is also interest in deliveringmore that one growth factor. However,
in the studies of Hou et al. [213], although ex vivo transfer of TGFβ cDNA
improved healing in a rabbit Achilles injury model, VEGF did not and
added nothing to the effectiveness of TGFβ. It is probable that different
growth factors will be needed at different times during the healing
process, in which case their genetic transfer will require staged delivery
of vectors with different transgenes, or single delivery of a polycistronic
vector with different, inducible promoters. The latter will be very difﬁcult
to navigate through the regulatory process and into human clinical use.
Inhibiting inﬂammation is an alternative approach to promote repair
and regeneration, and successful use of IL-10 cDNA in this regard has
been reported [216]. Anti-inﬂammatory gene products may also be of
therapeutic use in tendinitis. IGF-1 gene transfer has been explored as
a way of augmenting tendon structure in tendinitis [217].
Additional uses of gene transfer in treating tendinopathies are listed
in Table 5.
There is interest in using osteogenic genes to enhance the incorpora-
tion of tendon into the osseous insertion site after reconstructive surgery
[218–220]. Because the tendon at this site has a ﬁbrocartilagenous zone,
there is also the possibility to improve the function of the regenerate re-
pair by promoting the formation of cartilage in this important area
using chondrogenic genes [221,222].
Another application seeks to prevent the formation of fat or bone
within tendon, a risk when using multipotent progenitor cells as agents
of repair. In this case, the ex vivo use of tengogenic cDNAs, such as those
encoding scleraxis [122,211], SMAD8 [120] or the appropriate BMPTable 5
Use of gene transfer to address additional aspects of tendinopathy.
Gene Vector Delivery mode
Sox-9 Adenovirus In vivo
IGF-1 Adenovirus Ex vivo/MSC
BMP-4 Lentivirus In vivo
BMP-2 Adenovirus In vivo
MT1-MMP Adenovirus Ex vivo/MSC
siRNA-Runx2 Adenovirus In vivo
siRNA-Runx2, SMAD4 Adenovirus In vivo
shRNA-Decorin Lentivirus Ex vivo/tendon cwould steer the cells towards tenogenesis and prevent them from
differentiating along adipogenic or osteogenic lineages. Heterotopic
ossiﬁcation can also occur without the addition of such cells as a result
of injury. Inhibitory species of non-coding RNA that knockdown
Runx2 or SMAD4 have shown promise in blocking this process [223,
224]. Knockdown of decorin has been explored as a way of inhibiting
scar formation [225].2.4.5. Translation
Approval of clinical protocols for orthopedic applications of gene
therapy is a long, expensive and tedious process [226]. Although the lit-
erature, summarized here, holds promise of success for gene-based
technologies to regenerate tendons, the data are preliminary and re-
stricted to acute, small animal models. The optimal vector, transgene,
promoter and delivery mechanism still need to be determined. Efﬁcacy
then needs to be conﬁrmed in large animal models. Safety is a major
issue for all gene therapy protocols, especially those involving non-
lethal pathologies; the pharmacology and toxicology testing of gene ther-
apeutics is complicated. The cost of a therapeutic is also a large factor in
today's economic environment, which is one reason to favor expedited
approaches that do not require the ex vivo propagation of autologous
cells [191,192].3. Concluding remarks
Repair of tendon injuries is a lengthy process that frequently results in
poor structural, mechanical and functional quality of the healed tissue. At
present, the clinical options for treating tendon injuries are often unsatis-
factory, especially in elderly populations. Therefore, several alternative
strategies are being explored. The concept of biological therapy is attrac-
tive, because it makes use of the body's intrinsic potential to repair and
heal its damaged tissues [191]. When tissue regeneration is approached
in this manner, the result is expected to be natural, complete and lasting.
As noted in this review, promising experimental data support the concept
of using proteins, genes and cells, often in conjunction with biological
scaffolds, as agents of the biological repair of tendons. However, these
strategies are still in the stage of pre-clinical development and optimiza-
tion. To reach their full potential and become realistic clinical options, fur-
ther research focusing on solving critically important challenges is needed
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